4.24
-0.47%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Zhejiang CONBA Pharmaceutical Co
Its shares trade on Shanghai under the ticker 600572.SS. It has been listed since 12 April 2004. In the fiscal year to 31 December 2025, it reported revenue of CN¥6.47bn and net income of CN¥474.4m. At that date it held total assets of CN¥9.98bn and shareholders' equity of CN¥7.05bn.
Zhejiang Conba Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of pharmaceutical products. The company is headquartered in Hangzhou, Zhejiang. The company went IPO on 2004-04-12. The firm also provides active ingredients. The firm's products include tablets, capsules, pills, granules, powders, injections, oral solutions, syrups, eye drops, nasal drops, ear drops, ointments and others. Its products are applied in cardiovascular and cerebrovascular diseases, urinary system diseases, digestive diseases, respiratory diseases, endocrine system, nervous system, anti-infection and other treatment areas. The firm also provides value-added services. The firm distributes its products within domestic markets.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 12 Apr 2004
- Employees
- 8,415
- Website
- conbapharm.com ↗
Leadership
Pay as last reported
- Mr. Yi JiangChairman of the Board, President, since 2024
- Mr. Ming ShenChief Financial Officer, Finance Director, Vice President, since 2020CN¥1.3m
- Mr. Qi ShenChief Investment Officer, Vice President
- Mr. Luwen WuChief Marketing Officer, Director, since 2024
- Mr. Shishui YinChief Compliance Officer, Vice President, General Counsel
- Mr. Zucheng JinVice President, Secretary of the BoardCN¥1.3m
- Mr. Jianfeng YeVice President, Director, since 2023
- Ms. Chunling XuVice PresidentCN¥1.4m
- Ms. Qian JiangDirector
- Mr. Shengdong LiuDirector
- Ms. Taofang WangStaff Elected Director
- Mr. Yulong NiuIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 58
- Environment
- 68
- Social
- 80
- Governance
- 27
- Direct emissions (scope 1)
- 58,907.79 t
- Energy emissions (scope 2)
- 105,413.02 t
- Women in the workforce
- 52%
- Carbon reduction policy
- Yes
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Headquartered in Hangzhou, Zhejiang with 8,415 employees.
- Engages in R&D, production, and sale of pharmaceutical products.
- Offers a wide range of products including tablets, capsules, and injections.
Weaknesses
- Limited to domestic market distribution only.
- No mention of international market presence or expansion plans.
- Relies on traditional product categories without specified innovation.
Opportunities
- Potential to expand into international markets beyond domestic distribution.
- Growth in pharmaceutical sectors like cardiovascular and respiratory diseases.
- Value-added services could enhance customer retention and revenue.
Threats
- Dependence on domestic market may limit growth opportunities.
- Competition in pharmaceutical sectors could increase market pressure.
- Lack of specified innovation might hinder long-term competitiveness.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.